Quick Search
CAS NUMBER: 137862-53-4
EC NUMBER: 604-045-2
MOLECULAR FORMULA: C24H29N5O3
MOLECULAR WEIGHT: 435.5
Valsartan is a medicine used to treat high blood pressure, heart failure and diabetic kidney disease.
Valsartan is a reasonable initial treatment for high blood pressure.
Valsartan is an oral substance.
Valsartan versions are available as Valsartan/hydrochlorothiazide, Valsartan/amlodipine, Valsartan/amlodipine/hydrochlorothiazide or Valsartan/sacubitril combination.
Valsartan is an angiotensin II receptor antagonist.
Valsartan works by blocking the effects of angiotensin II.
Valsartan is available as a generic drug.
Valsartan is used to treat hypertension.
Valsartan is used to treat high blood pressure and heart failure.
Valsartan is also used to improve the chance of living longer after a heart attack.
In people with heart failure, it may also lower the chance of having to go to the hospital for heart failure.
Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs).
Valsartan works by relaxing blood vessels so that blood can flow more easily.
Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems.
How to use Valsartan:
Read the Patient Information Leaflet if available from your pharmacist before you start taking valsartan and each time you get a refill.
If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth with or without food as directed by your doctor, usually once or twice daily.
The dosage is based on your medical condition and response to treatment.
For children, the dosage is also based on weight.
If you are using the liquid form of this medication, shake the bottle well for at least 10 seconds before each dose.
Carefully measure the dose using a special measuring device/spoon.
Do not use a household spoon because you may not get the correct dose.
Use this medication regularly to get the most benefit from it.
To help you remember, take it at the same time(s) each day.
Keep taking this medication even if you feel well.
Valsartan is an angiotensin II receptor blocker.
Valsartan is associated with minor transient elevations of serum aminotransferases.
Valsartan has been associated with rare cases of acute liver injury.
Valsartan is a chemical compound that enables the synthesis and secretion of aldosterone.
Valsartan prevents renal reabsorption of sodium.
Valsartan is an amide of monocarboxylic acid. Valsartan shows antihypertensive activity.
Valsartan is a biphenyltetrazol, a monocarboxylic acid amide and a monocarboxylic acid.
Valsartan is a chemical compound in a form that is readily soluble in sodium hydroxide solution.
Valsartan is a chemical compound in the form of a white crystalline powder.
Valsartan is a practically odorless substance.
Valsartan is slightly soluble in water but well soluble in alcohol.
Valsartan is used in the treatment of hypertension to reduce the risk of cardiovascular events, particularly strokes and myocardial infarctions.
In addition, Valsartan is a very important component used in the treatment of heart failure.
Valsartan is used therapeutically for left ventricular dysfunction or failure after myocardial infarction for which the use of an angiotensin converting enzyme inhibitor is inappropriate.
Valsartan is necessary for treatment in adults whose blood pressure is not adequately controlled.
Valsartan is used alone or in combination with other agents to treat hypertension and reduce cardiovascular mortality after myocardial infarction.
Valsartan has known transformation products containing Valsartan acid.
Valsartan is a very important substance that significantly reduces hospitalization for heart failure.
Valsartan is widely used in the treatment of diabetes-associated nephropathy.
Most people with high blood pressure do not feel sick.
Valsartan is an angiotensin II receptor blocker (sometimes called an ARB).
Valsartan is used to treat high blood pressure (hypertension) in adults and children who are at least 1 year old.
Lowering blood pressure may lower your risk of a stroke or heart attack.
Valsartan is also used in adults to treat heart failure and lower your risk of needing to be hospitalized, and to lower your risk of death after a heart attack.
Valsartan may also be used for purposes not listed in this medication guide.
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease.
Valsartan is a reasonable initial treatment for high blood pressure.
Valsartan is taken by mouth.
Versions are available as the combination
Common side effects include feeling tired, dizziness, high blood potassium, diarrhea, and joint pain.
Other serious side effects may include kidney problems, low blood pressure, and angioedema.
Use in pregnancy may harm the baby and use when breastfeeding is not recommended.
Valsartan is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.
Valsartan was patented in 1990, and came into medical use in 1996.
Valsartan is available as a generic medication.
In 2018, it was the 96th most commonly prescribed medication in the United States, with more than 7 million prescriptions
Medical Uses:
Valsartan is used to treat the following Factors:
-high blood pressure
-heart failure
-to reduce death for people with left ventricular dysfunction after having a heart attack.
High Blood Pressure:
Valsartan is a reasonable initial treatment for high blood pressure as are
-ACE inhibitors
-calcium-channel blockers
-thiazide diuretics
Heart Failure:
There is contradictory evidence with regard to treating people with heart failure with a combination of an angiotensin receptor blocker like;
-valsartan and an angiotensin-converting enzyme inhibitor
-with two major clinical trials showing a reduction in death
-Good for hypotension
-good for renal dysfunction
Diabetic Kidney Disease:
In people with type 2 diabetes and high blood pressure or albumin in the urine, valsartan is used to slow the worsening and the development of end-stage kidney disease.
Contraindications:
The packaging for valsartan includes a warning stating the drug should not be used with the renin inhibitor aliskiren in people with diabetes.
Valsartan also states the drug should not be used in people with kidney disease.
Valsartan includes a black box warning for fetal toxicity.
Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be started.
Breastfeeding is not recommended
Valsartan also has kidney protective effects.
Valsartan creates drugs that provide improvements in chronic kidney disease.
Valsartan has very beneficial effects on urinary albumin and protein excretion in patients diagnosed with type 2 diabetes.
Valsartan is also prescribed after a heart attack to lower blood pressure and increase the patient's chances of living longer.
Valsartan is a very effective substance in regulating blood pressure.
Valsartan is a receptor antagonist that has important effects in maintaining the body's fluid balance.
Valsartan does not affect angiotensin converting enzymes or renin and its receptors.
Valsartan does not inhibit ion channels involved in blood pressure regulation and sodium balance.
Mechanism of Action:
Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure.
The drug binds to angiotensin type I receptors (AT1), working as an antagonist.
This mechanism of action is different than that of the ACE inhibitor drugs, which block the conversion of angiotensin I to angiotensin II.
As valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by other enzymes as well as ACE.
Also, valsartan does not affect the metabolism of bradykinin like ACE inhibitors do.
Pharmacokinetics:
AUC and Cmax values of valsartan are observed to be approximately linearly dose-dependent over therapeutic dosing range.
Owing to its relatively short elimination half life attribution, valsartan concentration in plasma doesn't accumulate in response to repeated dosing
Combinations:
Valsartan is combined with amlodipine or hydrochlorothiazide (HCTZ) (or both) into single-pill formulations for treating hypertension with multiple drugs.
Valsartan is also available as the combination valsartan/sacubitril.
Valsartan is used to treat heart failure with reduced ejection fraction
Shortages:
Since July 2018, numerous recalls of losartan, valsartan and irbesartan drug products have caused marked shortages of these life saving medications in North America and Europe, particularly for valsartan.
In March 2019, the FDA approved an additional generic version of Diovan™ to address the issue.
According to the agency, the shortage of valsartan was resolved in 3 April 2020,
but the availability of the generic form remained unstable into July 2020.
Pharmacies in Europe were notified that the supply of the drug, particularly for higher dosage forms, would remain unstable well into December 2020
Valsartan does not affect heart rate while lowering blood pressure.
Valsartan can be used for patients with uncomplicated hypertension.
Valsartan can be used as a first-line agent in the treatment of isolated systolic hypertension and left ventricular hypertrophy.
Valsartan can be used as a first-line agent to delay the progression of diabetic nephropathy.
Valsartan is a chemical compound in the form of fine powder, very close to white.
Valsartan is well soluble in DMSO.
Valsartan has a structure that exists in solid form.
USES OF VALSARTAN:
Valsartan can be used for patients with uncomplicated hypertension
Valsartan is widely used in the treatment of diabetes-associated nephropathy.
Valsartan is used alone or in combination with other agents to treat hypertension and reduce cardiovascular mortality after myocardial infarction.
Valsartan is used therapeutically for left ventricular dysfunction or failure after myocardial infarction for which the use of an angiotensin converting enzyme inhibitor is inappropriate.
Valsartan is used in the treatment of hypertension to reduce the risk of cardiovascular events, particularly strokes and myocardial infarctions.
Valsartan is used to treat hypertension.
Valsartan is a medicine used to treat high blood pressure, heart failure and diabetic kidney disease.
Valsartan is widely used to treat high blood pressure and heart failure.
Valsartan is usually used in drug form.
Valsartan is also sometimes used after a heart attack.
Valsartan is available in tablets, capsules and liquid form.
Valsartan is used alone or in combination with other medicines to treat high blood pressure (hypertension).
Valsartan is sometimes used to increase cardiac resistance.
Valsartan is used to reduce the risk of stroke and heart when taken in adequate doses.
Valsartan is frequently used in the manufacture of medical drugs.
Valsartan can also be used in chemical studies.
APPLICATIONS OF VALSARTAN:
-Nephropathy Treatment
-Hypertension Patients
-Pharmacy
-Therapeutic uses
-Cardiovascular risk reduction
-Biochemistry laboratories
-Heart failure treatment
-Kidney disease drugs
-Medical applications
-Drug forms
-Intermediate agents
-Resistance-enhancing supplements
-Bioengineering
Valsartan is a medicine widely used to treat high blood pressure and heart failure.
Valsartan's also sometimes prescribed after a heart attack.
Valsartan is only available on prescription.
Valsartan comes as tablets, capsules and as a liquid that you swallow.
Valsartan lowers your blood pressure and makes it easier for your heart to pump blood around your body.
Valsartan's often used as a second-choice treatment if you had to stop taking a similar medicine because it gave you a dry, irritating cough.
Valsartan is also called by the brand name Diovan.
Valsartan is used alone or together with other medicines to treat high blood pressure (hypertension).
High blood pressure adds to the workload of the heart and arteries.
If it continues for a long time, the heart and arteries may not function properly.
This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure.
Lowering blood pressure can reduce the risk of strokes and heart attacks.
PHYSICAL PROPERTIES OF VALSARTAN:
Molecular Weight: 435.5
Exact Mass: 435.22703980
Monoisotopic Mass: 435.22703980
Topological Polar Surface Area: 112 A
Physical Description: Solid
Color/Form: White to practically white fine powder
Boiling Point: 83-88 °C
Melting Point: 116-117 °C
Solubility: In water, 1.406 mg/L at 25 °C
Vapor Pressure: 8.18X10-16 mm Hg
Valsartan is also used to treat heart failure and left ventricular failure after a heart attack.
Left ventricular failure occurs when the left side of the heart (the main pumping chamber) becomes stiff and enlarged or swollen.
This causes pooling of blood in the lungs because the heart is not pumping properly.
Valsartan is an angiotensin II receptor blocker (ARB).
Valsartan works by blocking a substance in the body that causes blood vessels to tighten.
Valsartan relaxes the blood vessels and lowers blood pressure.
A lower blood pressure will increase the supply of blood and oxygen to the heart.
Valsartan is an angiotensin II receptor blocker used alone or in combination with other agents to treat hypertension and reduce cardiovascular mortality after myocardial infarction.
Valsartan is associated with a low rate of transient serum aminotransferase elevations and has been linked to rare instances of acute liver injury.
Valsartan is an orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties.
Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure.
CHEMICAL PROPERTIES OF VALSARTAN:
Covalently-Bonded Unit Count: 1
Compound Is Canonicalized: Yes
XLogP3-AA: 4.4
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 6
Rotatable Bond Count: 10
Heavy Atom Count: 32
Formal Charge: 0
Complexity: 608
Isotope Atom Count: 0
Defined Atom Stereocenter Count: 1
LogP: 1.499
Henrys Law Constant: 3.08X10-18 atm-cu m/mol
Collision Cross Section: 202 A
Stability: Hygroscopic
Valsartan is a monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group.
Valsartan exhibits antihypertensive activity.
Valsartan has a role as an antihypertensive agent, an angiotensin receptor antagonist, a xenobiotic and an environmental contaminant.
Valsartan is a biphenylyltetrazole, a monocarboxylic acid amide and a monocarboxylic acid.
Other Experimental Properties:
-White or practically white crystalline powder.
-Practically odorless.
-Slightly soluble in water, freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide;
-sparingly soluble in methanol;
-insoluble in ether, in chloroform, and in dilute mineral acids.
Drug Indication:
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Valsartan is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting enzyme inhibitor (ACEI) is not appropriate.
Treatment of essential hypertension.
Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy
Pharmacology:
Valsartan inhibits the pressor effects of angiotensin II with oral doses of 80 mg inhibiting the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours.
Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients.
Minimal decreases in plasma aldosterone were observed after administration of valsartan.
In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid.
Absorption:
After one oral dose, the antihypertensive activity of valsartan begins within approximately 2 hours and peaks within 4-6 hours in most patients.
Food decreases the exposure to orally administered valsartan by approximately 40% and peak plasma concentration by approximately 50%.
AUC and Cmax values of valsartan genereally increase linearly with increasing dose over the therapeutic dose range.
Valsartan does not accumulate appreciably in plasma following repetitive administration.
Route of Elimination:
Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose).
The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites
Volume of Distribution:
The steady state volume of distribution of valsartan after intravenous administration is small (17 L), indicating that valsartan does not distribute into tissues extensively.
Valsartan peak plasma concentration is reached 2 to 4 hours after dosing.
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
Absolute bioavailability for Diovan is about 25% (range 10% to 35%).
The bioavailability of the suspension is 1.6 times greater than with the tablet.
With the tablet, food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%.
AUC and Cmax values of valsartan increase approximately linearly with increasing dose over the clinical dosing range.
Valsartan does not accumulate appreciably in plasma following repeated administration.
Metabolism/Metabolites:
Valsartan undergoes minimal liver metabolism and is not biotransformed to a high degree, as only approximately 20% of a single dose is recovered as metabolites.
The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan.
In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.
Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations.
CYP 450 mediated drug interaction between valsartan and coadministered drugs are unlikely because of the low extent of metabolism.
Valsartan is known to be excreted largely as unchanged compound and is minimally metabolized in man.
Although the only notable metabolite is 4-hydroxyvaleryl metabolite (4-OH valsartan), the responsible enzyme has not been clarified at present.
The current in vitro studies were conducted to identify the cytochrome P450 (CYP) enzymes involved in the formation of 4-OH valsartan.
Valsartan was metabolized to 4-OH valsartan by human liver microsomes and the Eadie-Hofstee plots were linear.
The apparent Km and Vmax values for the formation of 4-OH valsartan were 41.9-55.8 microM and 27.2-216.9 pmol min(-1) mg(-1) protein, respectively.
There was good correlation between the formation rates of 4-OH valsartan and diclofenac 4'-hydroxylase activities (representative CYP2C9 activity) of 11 individual microsomes (r = 0.889).
No good correlation was observed between any of the other CYP enzyme marker activities (CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A).
Among the recombinant CYP enzymes examined (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and 4A11), CYP2C9 notably catalysed 4-hydroxylation of valsartan.
For the specific CYP inhibitors or substrates examined (furafylline, diclofenac, S(+)-mephenytoin, quinidine and troleandomycin), only diclofenac inhibited the formation of 4-OH valsartan.
These results showed that CYP2C9 is the only form responsible for 4-hydroxylation of valsartan in human liver microsomes.
Although CYP2C9 is involved in valsartan metabolism, CYP-mediated drug-drug interaction between valsartan and other co-administered drugs would be negligible.
Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose).
The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites.
The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan.
In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan. Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations.
CYP 450 mediated drug interaction between valsartan and coadministered drugs are unlikely because of the low extent of metabolism
STORAGE OF VALSARTAN:
Valsartan must be stored safely.
Valsartan should be kept in tightly closed containers.
Valsartan should be stored in a dry place.
Valsartan should be stored in a well-ventilated place.
Valsartan, preferably should be stored between +2 and +8 °C.
Valsartan should be handled with a dry substance.
Valsartan can be stored at +25 °C for short-term use.
Valsartan can be kept between +15°C and +20°C during transport.
Valsartan should be kept away from moisture.
Valsartan can be stored for more than 2 years at -20°C.
Valsartan should be stored away from substances that may react with it.
Valsartan can preferably be stored in glass bottles.
Valsartan can also be contained in medicine capsules and special plastic tablets.
Biological Half-Life:
After intravenous (IV) administration, valsartan demonstrates bi-exponential decay kinetics, with an average elimination half-life of about 6 hours
Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours.
In an investigation of pharmacokinetics and pharmacodynamics in normotensive male volunteers, valsartan was rapidly absorbed with the maximal plasma concentration occurring 2-3 hr after oral administration.
The elimination half-life was about 4-6 hr, valsartan was poorly metabolized, and most of the drug was excreted via feces
Mechanism of Action:
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which selectively bind to angiotensin receptor 1 (AT1) and prevent angiotensin II from binding and exerting its hypertensive effects.
These include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium among others.
Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions.
Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease.
In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.
ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and prevent ventricular hypertrophy.
The angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibits the conversion of angiotensin I to angiotensin II by inhibiting the ACE enzyme but does not prevent the formation of all angiotensin II.
ARB activity is unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized.
Valsartan is commonly used for the management of hypertension, heart failure, and type 2 diabetes-associated nephropathy, particularly in patients who are unable to tolerate ACE inhibitors.
ARBs such as valsartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.
Valsartan also slows the progression of diabetic nephropathy due to its renoprotective effects.
Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed with type 2 diabetes and in nondiabetic patients diagnosed with chronic kidney disease.
Valsartan also binds to the AT2 receptor, however AT2 is not known to be associated with cardiovascular homeostasis like AT1.
Valsartan has about 20,000-fold higher affinity for the AT1 receptor than for the AT2 receptor.
The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor.
Valsartan, a nonpeptide tetrazole derivative, is an angiotensin II type 1 (AT1) receptor antagonist.
Valsartan has pharmacologic actions similar to those of losartan; however, unlike losartan, valsartan is not a prodrug and its pharmacologic activity does not depend on hydrolysis in the liver.
Valsartan blocks the physiologic actions of angiotensin II, including vasoconstrictor and aldosterone-secreting effects, by selectively inhibiting access of angiotensin II to AT1 receptors within many tissues, including vascular smooth muscle and the adrenal gland.
By comparison, angiotensin-converting enzyme (ACE, kininase II) inhibitors block the conversion of angiotensin I to angiotensin II; however, the blockade of angiotensin II production by ACE inhibitors is not complete since the vasopressor hormone can be formed via other enzymes that are not blocked by ACE inhibitors.
Because valsartan, unlike ACE inhibitors, does not inhibit ACE, the drug does not interfere with response to bradykinins and substance P; a beneficial consequence is the absence of certain ACE inhibitor-induced adverse effects (e.g., cough), but possible renal and/or cardioprotective effects may be sacrificed.
Valsartan also does not interfere with angiotensin II synthesis.
Analytic Laboratory Methods:
A simple, precise, accurate stability-indicating gradient reverse phase ultra-performance liquid chromatographic (RP-UPLC) method was developed for the quantitative determination of purity of Valsartan drug substance and drug products in bulk samples and pharmaceutical dosage forms in the presence of its impurities and degradation products.
The method was developed using Waters Aquity BEH C18 (100 mm x 2.1 mm, 1.7 microm) column with mobile phase containing a gradient mixture of solvents A and B.
The eluted compounds were monitored at 225 nm, the run time was within 9.5 min, which valsartan and its seven impurities were well separated.
Clinical Laboratory Methods:
A high-performance liquid chromatographic (HPLC) method for the determination of valsartan in human plasma is reported.
The assay is based on protein precipitation with methanol and reversed-phase chromatography with fluorimetric detection.
The limit of quantitation was 98 ng/mL using 0.2 mL of plasma.
Storage Conditions:
Conditions for safe storage:
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature:
2 - 8 °C Store with desiccant.
SYNONYMS:
Diovan
(S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
Kalpress
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine
Valzaar
Prexxartan
Valpression
Varexan
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
(2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
Valsartan, European Pharmacopoeia (EP) Reference Standard
N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine
Valsartan, United States Pharmacopeia (USP) Reference Standard
N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine
Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material
(5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid
(S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid
